NEW BRUNSWICK, N.J., May 7 /PRNewswire-FirstCall/ -- Johnson & Johnson
will provide a pre-recorded webcast for financial analysts on Friday, May 9
at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's
(APS) annual meeting in Tampa, Fla. Phase 3 clinical data presentations on
investigational tapentadol immediate release (IR), a novel centrally acting
oral analgesic, will be presented for the first time at APS.
A pre-recorded Webcast, with the lead tapentadol researchers, will be
made available concurrent to the data presentations being made during the
poster session at APS. Pre-registration is not required to view the
webcast/podcast.
The presentation will provide an overview on tapentadol IR and review
data from the following clinical posters:
-- Efficacy of Tapentadol Immediate Release in Patients With Pain After
Bunionectomy
-- Analgesic Efficacy of Tapentadol Immediate Release in Patients With
Pain From End-Stage Joint Disease
-- Tapentadol Immediate Release is Associated With Improved
Gastrointestinal Tolerability Compared With Oxycodone Immediate Release
Over 90 Days in Patients With Lower Back or Osteoarthritis Pain
The webcast/podcast and replay can be accessed by clicking on
"Webcasts/Presentations" in the Investor Relations section of the Company's
website at http://www.jnj.com.
SOURCE Johnson & Johnson
 back to top
Related links:
http://www.jnj.com
http://www.prnewswire.com/comp/467347.html /
CONTACT:
Investors - Louise Mehrotra, +1-732-524-6491,
or Lesley Fishman, +1-732-524-3922
|
